Zinc supplementation ameliorates type 2 diabetes markers through the enhancement of total antioxidant capacity in overweight patients

Abstract

Background Evidence show that the recommended dose of zinc may not be sufficient for controlling pathological conditions such as type 2 diabetes mellitus (T2DM). Aim This study aimed to evaluate the effects of zinc supplementation on the oxidative status in overweight T2DM. In addition, the routine glycaemic parameters were determined and compared in zinc-treated and placebo groups. Methods In this randomised, double-blind, placebo-controlled trial, 70 patients with T2DM were selected. They were divided into two groups for supplementation of 50 mg zinc gluconate or placebo (zinc group, n=35; placebo group, n=35) per day for 8 weeks. Blood samples were collected from all the individuals in the zinc group and controls for analysis. Results The results showed that zinc supplementation to patients with T2DM for 8 weeks significantly inhibited serum levels of lipid peroxidation (25%), nitrotyrosine (30%) and total oxidant status levels (25%, p<0.05). Nevertheless, the total antioxidant capacity was significantly elevated (16%) following zinc intake by patients with T2DM. Conclusions These data, together with our previous report, may suggest that the control in the glycaemic condition in overweight patients with T2DM is correlated with the antioxidative/oxidative balance following intake of 50 mg zinc supplementation for 8 weeks. Under these circumstances, the clinical and glycaemic indices, including fasting blood glucose, insulin, haemoglobin A1c and homeostasis model of assessment–insulin resistance, were controlled. Trial registration number NCT2015083102.

Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets

“…The clinical and glycemic indices. IRCT2015083102 687 Diabetes with thalassemia 25 mg zinc sulfate/day, 3 months. Zinc supplementation improves glucose homeostasis in thalassemia.…”

Nutritional therapy bridges the critical cut-off point for the closed-loop role of type 2 diabetes and bone homeostasis: A narrative review

“…T2DM is usually associated with polyuria zinc loss, leaving the body in a state of zinc deficiency, and the mechanism of action of zinc supplementation in alleviating glycolipid abnormalities and modulating antioxidant impairment in T2DM has been consistently demonstrated in long-term studies [ 65 , 81 , 82 ]. Secondly, zinc is not only a component of bone tissue but also a bone protective factor that counteracts the development of OP and is essential for bone collagen matrix synthesis, mineralization, and bone turnover [ 83 ].…”

Beta Cell Dysfunction in Youth- and Adult-Onset Type 2 Diabetes: An Extensive Narrative Review with a Special Focus on the Role of Nutrients

“…Zinc has been shown to modulate metallothionein expression and glutathione metabolism, to act as a superoxide dismutase cofactor, to compete with iron and copper in the β-cell membrane, and to inhibit enzymes involved in the inflammatory process [235]. Indeed, studies with zinc supplementation in overweight T2DM patients have shown an improvement in disease markers through enhancement of their total antioxidant capacity [236,237]. In addition, a study with rats made diabetic by injecting a single streptozotocin dose showed that the combined administration of zinc, selenium, and vitamin E had the best anti-oxidative result and improved glycemic control more than the antidiabetic drug glibenclamide [238].…”